Self-reactive anti-neutrophil cytoplasmic antibodies, or ANCAs, may play a unique role in driving blood vessel inflammation in people with eosinophilic granulomatosis with polyangiitis (EGPA), the rarest form of ANCA-associated vasculitis (AAV). That’s according to a small study, which found that disease relapses outside the respiratory system occurred only in EGPA…
ANCAs may hold unique role in vessel inflammation with EGPA
I seriously did not have time for this. I did not have time to get sick. Not now. Those were my thoughts when I finally received a diagnosis of eosinophilic granulomatosis with polyangiitis, or EGPA, during the busy holiday season in late 2015. I had my kids’ holiday…
Evotec has formed a partnership with Charité – Universitätsmedizin Berlin in Germany to build a database of all sorts of molecular information from people with ANCA-associated vasculitis (AAV). Molecular profiles, a kind of fingerprint of AAV, may help scientists better understand the autoimmune disease and pave the way…
As a child, I always used to check out travel and cooking books from my local library. I’d daydream about foreign places and exotic foods and couldn’t wait to see the world. Some might say I had my head in the clouds. Soon after graduating from college, I married and…
Factor XII (FXII), a protein involved in blood clotting, is found at significantly higher levels in the blood of people with active ANCA-associated vasculitis (AAV) relative to those in clinical remission, or whose symptoms have eased or disappeared. That’s according to a study in China that also found that…
ANCA-associated vasculitis (AAV) with kidney involvement is the most common cause of kidney disease among elderly people, but most older patients appear to benefit from appropriate therapy as well as younger AAV patients with kidney damage. That’s according to a study in Germany that found no significant differences in…
A first patient has been dosed in a Phase 2 clinical trial testing lixudebart, Alentis Therapeutics‘ investigational antibody therapy, in ANCA-associated vasculitis (AAV) patients with rapidly progressing glomerulonephritis (RPGN), a serious kidney disease. The study, RENAL-F02 (NCT06047171), currently is recruiting up to 60 adults with AAV…
ANCA-associated vasculitis (AAV) patients who are older and taking pulses of methylprednisolone as an induction therapy are more likely to have a greater drop in protective IgG antibody levels during maintenance therapy with rituximab, raising a significant risk of severe infections, a study from France reports. A lower…
Common variants in genes that encode proteins of the alternative complement pathway, a part of the immune system, may raise the risk of ANCA-associated vasculitis (AAV) and severe disease-related kidney damage, a study shows. Researchers also found a link between worse disease outcomes and AAV…
In a Phase 3 trial of Tavneos (avacopan) in people with ANCA-associated vasculitis (AAV), the therapy’s effectiveness in the subgroup of patients on standard induction treatment with rituximab was similar to that of the overall study population. Reasonable safety also was seen, and sustained one-year remission was higher…
Recent Posts
- Using the spoon theory to manage my energy with chronic illness
- FDA proposes removing Tavneos from market over data concerns
- Testing iron protein in blood may improve AAV monitoring and care
- Even with ANCA vasculitis, we can be awe-struck by our own bodies
- Current adult AAV criteria better at classifying the disease in children